

Decarboxylative Trifluoromethylation of Aliphatic Carboxylic Acids

Jacob A. Kautzky,[‡] Tao Wang,[‡] Ryan W. Evans, and David W. C. MacMillan^{*†}

Merck Center for Catalysis at Princeton University, Princeton, New Jersey 08544, United States

Supporting Information


ABSTRACT: Herein we disclose an efficient method for the conversion of carboxylic acids to trifluoromethyl groups via the combination of photoredox and copper catalysis. This transformation tolerates a wide range of functionality including heterocycles, olefins, alcohols, and strained ring systems. To demonstrate the broad potential of this new methodology for late-stage functionalization, we successfully converted a diverse array of carboxylic acid-bearing natural products and medicinal agents to the corresponding trifluoromethyl analogues.

In drug discovery, a commonly used strategy to protect against *in vivo* metabolism involves the incorporation of a trifluoromethyl group (CF₃) into medicinal candidates. Moreover, a variety of studies have shown that CF₃ groups can increase the efficacy of a drug candidate by modulating protein–ligand interactions and improving membrane permeance, among other benefits.¹ While significant advancements have been made in the development of general, catalytic protocols that access aryl–CF₃ adducts, methods for the formation of aliphatic C_{sp3}–CF₃ bonds remain limited.² Conventional approaches toward C_{sp3}–CF₃ installation include (i) difunctionalization of olefins via CF₃ radical addition,³ (ii) nucleophilic substitution of alkyl halides or triflates with stoichiometric [CuCF₃] species,⁴ and (iii) oxidative coupling of alkyl boronic acids with [CuCF₃] reagents.⁵ These elegant methods nonetheless require the pre-activation of the coupling partner, a step that can often limit their potential utility in late-stage functionalization and other diversification steps. As such, the discovery of a catalytic trifluoromethylation mechanism that allows the conversion of native, abundant functional groups into C_{sp3}–CF₃ motifs should be of considerable value to medicinal chemists and the synthetic community as a whole.


The merger of transition metal and photoredox catalysis, termed metallaphotoredox catalysis, has enabled the discovery of a range of synthetically valuable and hitherto elusive transformations.⁶ In particular, carboxylic acids, a naturally abundant class of compounds, can efficiently undergo decarboxylative cross-coupling via this dual catalysis platform to install a myriad of valuable functionalities including C_{sp3}–aryl, –alkyl, –vinyl, and –acyl groups.⁷ Indeed, the capacity of carboxylic acids to act as an adaptive functionality renders them ideal starting materials for both early- and late-stage bond formation. Moreover, these methodologies generally employ mild conditions (i.e., visible light, room temperature) and exhibit broad functional group tolerance, features that allow for their use with a diverse array of complex, biologically relevant molecules.⁸ Recently, we questioned if a metallaphotoredox

platform might enable a catalytic decarboxylative trifluoromethylation. As a key design element, we envisioned the use of copper as the key cross-coupling catalyst, effectively taking advantage of Cu^{III}'s propensity to undergo facile reductive elimination from its high valency oxidation state.⁹ At the same time, we hoped that C_{sp3}–carboxylic acid bonds could be activated via photoredox to generate alkyl radicals that would rapidly engage in a copper catalytic cycle. Indeed, it is well-established that aliphatic open-shell intermediates will undergo capture by copper species at rates that approach rates of diffusion.¹⁰ This concept was recently employed by our laboratory in a C–N heteroaryl bond-forming reaction wherein aliphatic carboxylic acids underwent decarboxylative coupling with many classes of *N*-nucleophiles.¹¹ Herein, we report the successful translation of this new strategy to C–C bond formation and describe the first copper-catalyzed decarboxylative trifluoromethylation of aliphatic carboxylic acids.


Impact of Trifluoromethyl Group in Drug Design



- improved metabolic stability
- increased membrane permeance
- favorable protein–ligand interactions

Traditional Methods of Constructing C_{sp3}–CF₃ Bonds

This Work: Trifluoromethylation of Aliphatic Carboxylic Acids




Details of the proposed dual copper-photoredox cycle are outlined in Scheme 1. We envisioned that photoexcitation of the Ir^{III} photocatalyst Ir[dF(CF₃)ppy]₂(4,4'-dCF₃bpy)PF₆ (**1**) with visible light would generate the highly oxidizing excited-state ^{*}Ir^{III} **2** (*E*_{1/2}^{red}[^{*}Ir^{III}/Ir^{III}] = 1.65 V vs SCE in MeCN).¹² At


Received: March 8, 2018

Published: May 14, 2018




Table 1. Decarboxylative Trifluoromethylation: Initial Studies^a

CF₃ sources




Umemoto reagent

14



Togni's reagent II

15




Togni's reagent I

11

^aPerformed with acid **3** (0.05 mmol), photocatalyst **1** (1 mol%), Cu source (20 mol%), bathophenanthroline (30 mol%), 2-*tert*-butyl-1,1,3,3-tetramethylguanidine (BTMG, 0.5 equiv), CF₃ source (1.25 equiv), and H₂O (30 equiv) in EtOAc (0.025 M). ^bYields by ¹⁹F NMR analysis. Yields in parentheses are isolated yields. ^cThe ligand 3,4,7,8-tetramethyl-1,10-phenanthroline was used on the Cu catalyst.

addition of 30 equiv of water further improved the reaction efficiency (entry 5, 78% isolated yield). It is worth noting that both Cu^{I} and Cu^{II} salts are capable precatalysts for this transformation. When Cu^{I} sources such as CuCN are used, a significant change in color can be observed upon addition of Togni's reagent 1, potentially due to a change in oxidation state of the copper species. This hypothesis is supported by *in situ* ^{19}F NMR analysis, in which an equivalent of Togni's reagent is consumed upon mixing with a ligated Cu^{I} species (see Supporting Information (SI) for details). It should be noted that sub-stoichiometric base (0.5 equiv, cf. Table 1, entry 6) is critical to the success of the reaction. Carboxylates are prone to form chelates with copper and deactivate the Cu catalyst.¹⁷ The tertiary alcohol byproduct originating from Togni's reagent 1 after transfer of the CF_3 moiety ultimately serves as stoichiometric base (cf. 13 to 4). Control experiments revealed that photocatalyst, copper catalyst, and light were all essential for the success of this new decarboxylative trifluoromethylation protocol (Table 1, entries 7–9). With respect to the proposed mechanism, it is important to note that $[\text{CuCF}_3]$ was not detected by ^{19}F NMR analysis (<1 mol%). This mechanism contrasts with the recent studies of the Li group, whereby stoichiometric $\text{Cu}(\text{CF}_3)_x$ was used to capture alkyl radicals.¹⁸ Moreover, mechanistic experiments reveal a copper-mediated decarboxylation is likely operative (see SI for details).

With optimized conditions in hand, we sought to evaluate the scope of the $\text{C}_{\text{sp}^3}\text{-CF}_3$ bond-forming reaction. As shown in [Table 2](#), a myriad of primary carboxylic acids are successful


Table 2. Scope of Decarboxylative Trifluoromethylation of Aliphatic Carboxylic Acids via Copper and Photoredox Catalysis^a

^aPerformed on a 0.5 mmol scale. Due to volatility of products, yields were obtained by ¹⁹F NMR analysis of the crude reaction mixtures using an internal standard. Isolated yields are provided in parentheses. See SI for isolation conditions and yields. ^bReaction performed under modified conditions. See SI for details.

substrates, providing the corresponding CF₃ analogue in good to excellent yield. Phenylacetic acids are generally competent, with a diverse range of electron-withdrawing (**16–19**, 70–80% yield), electron-donating (**20**, 74% yield), and electron-neutral substituents (**21** and **22**, 60 and 70% yield, respectively) tolerated on the aryl ring. Notably, the efficacy of the reaction was not hindered by *ortho* substitution (**20**, 74% yield), and useful levels of efficiency were observed for an *ortho,ortho*-disubstituted heterocycle (**26**, 30% yield). Notably, boronic esters and aryl bromides were also tolerated using this mild copper-catalyzed protocol, with no chemoselectivity issues (**17** and **21**, 80 and 60% yield, respectively). The reaction is also amenable to a range of non-benzylic primary acids (**27–33**, 31–82% yield). Moreover, substrates incorporating β,β -branching afforded the desired product in good yields (**31**

and **32**, 63 and 71% yield, respectively) revealing that steric constraints can be overcome. Gratifyingly, an array of heterocycles, many of which include basic nitrogens, can be utilized in this transformation (**23–26** and **28–30**, 30–70% yield).

We next turned our attention to secondary and tertiary carboxylic acids (**34–51**, 45–93% yield). We were pleased to find that cyclic carboxylic acids, including strained 3- and 4-membered rings, participate in this trifluoromethylation in moderate to excellent yield (**39–45**, 45–83% yield). Several bicyclic and spirocyclic compounds (**38**, **39**, **42**, and **45**, 45–83% yield) formed the desired bond with good efficiency. This is a significant finding given that many of these bicyclic systems serve as aryl ring bioisosteres in drug design.¹⁹ Moreover, acyclic systems also produced the desired CF₃ product in good

Table 3. Late-Stage Decarboxylative Trifluoromethylation of Natural Products and Medicinal Agents Containing Carboxylic Acids^a

^aAll yields are isolated. Performed with acid (0.5 mmol), Ir[dF(CF₃)ppy]₂(dtbbpy)PF₆ (1 mol%), CuCl₂ (20 mol%), 3,4,7,8-tetramethyl-1,10-phenanthroline (Me₄phen, 2.5 mol%), 2-*tert*-butyl-1,1,3,3-tetramethylguanidine (BTMG, 0.5 equiv), Togni's reagent I (1.25 equiv), and H₂O (30 equiv) in EtOAc (0.025 M). ^bPerformed with di(2-pyridyl) ketone and 1,1,3,3-tetramethylguanidine (TMG) in lieu of Me₄phen and BTMG, and no water was added.

efficiency (**46–48**, 50–56% yield). Notably, the compatibility of this reaction with medicinally relevant structures was demonstrated with a β -lactam (**46**, 53% yield). Last, a number of tertiary carboxylic acids were also successfully converted to C_{sp3}–CF₃ bonds in excellent yield (**49–51**, 87–93% yield).

To further demonstrate the utility of this decarboxylative trifluoromethylation protocol, we performed a series of late-stage modifications on medicinal agents and natural products (Table 3). To our delight, a large variety of biologically relevant systems that incorporate olefins, carbonyls, alcohols, and heterocycles underwent chemoselective installation of a CF₃ moiety (**52–63**, 30–71% yield). Remarkably, mupirocin was transformed in good yield, a notable finding given that this natural product incorporates an epoxide, a diol, and a Michael acceptor (**63**, 45% yield).

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.8b02650.

General experimental protocols, procedure for optimization studies, general procedure for decarboxylative trifluoromethylation, mechanistic studies, characterization data for all key compounds, and spectral data (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*dmacmill@princeton.edu

ORCID

David W. C. MacMillan: 0000-0001-6447-0587

Author Contributions

[‡]J.A.K. and T.W. contributed equally.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

Financial support was provided by the NIHGM (RO1 GM103558-05), and kind gifts from Merck, BMS, Pfizer, Janssen, and Eli Lilly are acknowledged. J.A.K. thanks the NSF GRFP (DGE 1656466) for funding.

■ REFERENCES

- (1) (a) Hagmann, W. K. *J. Med. Chem.* **2008**, *51*, 4359. (b) Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. *Chem. Soc. Rev.* **2008**, *37*, 320. (c) Müller, K.; Faeh, C.; Diederich, F. *Science* **2007**, *317*, 1881. (d) Bégue, J. P.; Bonnet-Delpon, D. *Bioorganic and Medicinal Chemistry of Fluorine*; J. Wiley & Sons: Hoboken, NJ, 2008.
- (2) Alonso, C.; de Marigorta, E. M.; Rubiales, G.; Palacios, F. *Chem. Rev.* **2015**, *115*, 1847.
- (3) (a) Merino, E.; Nevado, C. *Chem. Soc. Rev.* **2014**, *43*, 6598. (b) He, Z.; Tan, P.; Hu, J. *Org. Lett.* **2016**, *18*, 72. (c) Xu, X.; Chen, H.; He, J.; Xu, H. *Chin. J. Chem.* **2017**, *35*, 1665.
- (4) (a) Chen, Q.-Y.; Wu, S.-W. *J. Chem. Soc., Chem. Commun.* **1989**, 705. (b) Chen, Q.-Y.; Duan, J.-X. *Tetrahedron Lett.* **1993**, *34*, 4241. (c) Novak, P.; Lishchynskyi, A.; Grushin, V. V. *J. Am. Chem. Soc.* **2012**, *134*, 16167. (d) Tyrra, W.; Naumann, D.; Quad, S.; Buslei, S.; Yagupolskii, Y. L.; Kremlev, M. M. *J. Fluorine Chem.* **2007**, *128*, 813. (e) Sevenard, D. D. V.; Kirsch, P.; Roschenthaler, G. V.; Movchun, V. N.; Kolomeitsev, A. A. *Synlett* **2001**, *2001*, 379.
- (5) (a) Xu, J.; Xiao, B.; Xie, C. Q.; Luo, D. F.; Liu, L.; Fu, Y. *Angew. Chem., Int. Ed.* **2012**, *51*, 12551.
- (6) Twilton, J.; Le, C.; Zhang, P.; Shaw, M. H.; Evans, R. W.; MacMillan, D. W. C. *Nature Rev.* **2017**, *1*, 0052.
- (7) Jin, Y.; Fu, H. *Asian J. Org. Chem.* **2017**, *6*, 368.
- (8) Bloom, S.; Liu, C.; Kölmel, D. K.; Qiao, J. X.; Zhang, Y.; Poss, M. A.; Ewing, W. R.; MacMillan, D. W. C. *Nat. Chem.* **2018**, *10*, 205.

- (9) Liu, L.; Zhu, M.; Yu, H.-T.; Zhang, W.-X.; Xi, Z. *J. Am. Chem. Soc.* **2017**, *139*, 13688.
- (10) Freiberg, M.; Meyerstein, D. *J. Chem. Soc., Faraday Trans. 1* **1980**, *76*, 1825.
- (11) Liang, Y.; Zhang, X.; MacMillan, D. W. C. *ChemRxiv* **2018**, DOI: [10.26434/chemrxiv.5877868.v1](https://doi.org/10.26434/chemrxiv.5877868.v1).
- (12) Choi, G. J.; Zhu, Q.; Miller, D. C.; Gu, C. J.; Knowles, R. R. *Nature* **2016**, *539*, 268.
- (13) Charpentier, J.; Früh, N.; Togni, A. *Chem. Rev.* **2015**, *115*, 650.
- (14) Huang, Y.; Fang, X.; Lin, X.; Li, H.; He, W.; Huang, K.-W.; Yuan, Y.; Weng, Z. *Tetrahedron* **2012**, *68*, 9949.
- (15) (a) Umemoto, T. *Chem. Rev.* **1996**, *96*, 1757. (b) Shibata, N.; Matsnev, A.; Cahard, D. *Beilstein J. Org. Chem.* **2010**, *6*, 65.
- (c) Charpentier, J.; Früh, N.; Togni, A. *Chem. Rev.* **2015**, *115*, 650.
- (d) Chachignon, H.; Cahard, D. *Chin. J. Chem.* **2016**, *34*, 445.
- (16) Mizuta, S.; Verhoog, S.; Wang, X.; Shibata, N.; Gouverneur, V.; Médebielle, M. *J. Fluorine Chem.* **2013**, *155*, 124.
- (17) Vantourout, J. C.; Miras, H. N.; Isidro-Llobet, A.; Sproules, S.; Watson, A. J. B. *J. Am. Chem. Soc.* **2017**, *139*, 4769.
- (18) (a) Shen, H.; Liu, Z.; Zhang, P.; Tan, X.; Zhang, Z.; Li, C. *J. Am. Chem. Soc.* **2017**, *139*, 9843. (b) Tan, X.; Liu, Z.; Shen, H.; Zhang, P.; Zhang, Z.; Li, C. *J. Am. Chem. Soc.* **2017**, *139*, 12430.
- (19) (a) Patani, G. A.; LaVoie, E. J. *Chem. Rev.* **1996**, *96*, 3147.
- (b) Meanwell, N. A. *J. Med. Chem.* **2011**, *54*, 2529.